Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices 63841 

are the source of IL–13, and are 

activated by CD1 expressing intestinal 

epithelial cells. Tissue removed from 

UC patients were also shown to contain 

increased numbers of nonclassical NKT 

cells that produce markedly increased 

amounts of IL–13. In addition, these 

NKT cells are cytotoxic for epithelial 

cells, supporting the concept that 

epithelial damage is a key factor in UC. 

Applications: Development of IL–13 

and CD1 based therapeutics to treat or 

prevent ulcerative colitis. 

Development Status: Small animal 

model studies. 

Inventors: Warren Strober, Ivan Fuss, 

Frank Heller, Richard Blumberg 

(NIAID). 

Related Publications: 

1. IJ Fuss et al. Nonclassical CD1drestricted NK T cells that produce IL–13 

characterize an atypical Th2 response in 

ulcerative colitis. J Clin Invest. 2004 

May;113(10):1490–1497. [PubMed: 

15146247]. 

2. F Heller et al. Oxazolone colitis, a 

Th2 colitis model resembling ulcerative 

colitis, is mediated by IL–13-producing 

NK–T cells. Immunity 2002 

Nov;17(5):629–638. [PubMed: 

12433369]. 

Patent Status: 

• U.S. Patent No. 7,666,411 issued 23 

Feb 2010 (HHS Reference No. E–131– 

2002/0–US–02). 

• U.S. Patent Application No. 12/ 

709,029 filed 19 Feb 2010 (HHS 

Reference No. E–131–2002/0–US–10). 

• International patent/patent 

application filings. 

Related Technologies: Related IBD 

technologies also available for licensing 

include IL–13 mutant and chimeric 

molecules (HHS Reference No. E–003– 

2005/0) and NF-kappa B decoy 

oligonucleotides (HHS Reference No. 

E–108–2005/0). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Sury Vepa, PhD, 

J.D.; 301–435–5020; 

vepas@mail.nih.gov. 

Dated: October 12, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–26153 Filed 10–15–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Mouse Anti-Mouse CXCL9 (Mig) 

Monoclonal Antibodies 

Description of Invention: This 

technology describes monoclonal 

antibodies against mouse chemokine 

(C–X–C motif) ligand 9 (CXCL9), also 

known as Monokine induced by gamma 

interferon (Mig). CXCL9 is a secreted 

protein that functions to attract white 

cells and increased expression of CXCL9 

has been linked to several diseases. The 

inventors at the NIH generated over 100 

anti-mouse CXCL9 antibodies from a 

CLXL9/Mig knockout mouse and further 

characterized several antibodies to show 

neutralization of CXCL9. As such, these 

antibodies could be used to measure 

concentrations of mouse CLXL9 in 

laboratory samples and block the 

activity of CXCL9 in injected mice. 

These antibodies are suitable for ELISA 

and Western blot. The antibodies have 

not been tested in flow cytometry or 

immunohistochemistry, but may also be 

useful for these applications. 

Applications 

• ELISA assays for detection and 

measurement of CXCL9. 

• Neutralization of CXCL9 activity in 

mouse models and in vitro assays to 

study the role of CXCL9 in immune 

response and disease. 

Advantages: Can be used in mice 

without eliciting endogenous antibodies 

reacting against the injected antiCXCL9. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Joshua M. Farber and 

Hongwei H. Zhang (NIAID). 

Patent Status: HHS Reference No. 

E–198–2009/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status 

Available for licensing. 

Licensing Contact: Whitney A. 

Hastings; 301–451–7337; 

hastingw@mail.nih.gov. 

Signal-to-Noise Enhancement in 

Imaging Applications Using a TimeSeries of Images 

Description of Invention: The 

invention offered for licensing relates to 

the field of imaging and specifically to 

the field of medical imaging. The 

apparatus and method of the invention 

provide for noise reduction in imaging 

applications that use a time-series of 

images. In one embodiment of the 

invention, a time-series of images is 

acquired using a same imaging protocol 

of the same subject area, but the images 

are spaced in time by one or more time 

intervals (e.g., 1, 2, 3 * * * seconds 

apart). A sub-region is projected across 

all of the images to perform a localized 

analysis (corresponding X–Y pixels or 

X–Y–Z voxels are analyzed across all 

images) that identifies temporal 

components within each sub-region. 

Subsequently, within the sub-regions, 

only those temporal components are 

selected whose amplitude is above a 

predetermined amplitude threshold. 

The images are then reconstructed using 

the sub-regions with reduced 

components. A maximal-intensityprojection (MIP) is applied in the 

temporal domain (tMIP) in order to 

obtain a single image with reduced 

noise (this can be done either at the subregion level or at the reconstructed 

image level). The technology can be 

applied to a broad spectrum of medical 

imaging technologies such as MRI, XRay, CT and others. 

Applications: Medical imaging and 

diagnostics applied to MRI, X-Ray, CT 

scans or other imaging modalities 

including PET, SPECT, ultrasound or 

optical. 

Advantages: Enhancing signal-tonoise of medical imaging techniques. 

Development Status 

• Proof of concept has been 

demonstrated. Data is available. 

mstockstill on DSKH9S0YB1PROD with NOTICES

63842 Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices 

• Need to acquire further data to 

establish clinical utility of the method 

and to further optimize the protocol. 

Market 

• According to market research 

reports the market for medical imaging 

equipment industry in the United States 

is approximately $9.0 billion now and 

has been growing by approximately 

7.6% annually. 

• The United States market for 

computed tomography (CT) scanning 

systems is estimated to touch $3.6 

billion by the end of 2009. The U.S. 

accounts for over 50.0% of the 

worldwide market. 

• Worldwide MRI equipment market 

is estimated to reach $5.5 billion by 

2010, according to new report by Global 

Industry Analysts, Inc. (http://www.

strategyr.com/Magnetic_Resonance_

Imaging_MRI_Equipment_Market_

Report.asp). In the United States the 

market for such equipment is estimated 

at $1.9 billion for 2008, as stated the 

same report. The very high-field MRI 

systems market in the United States is 

projected to reach $968 million by the 

year 2010. Very High-Field Systems also 

represent the fastest growing segment, 

as hospitals and clinics upgrade old 

equipment with state-of-the-art systems. 

• Enhancements in imaging 

technologies to achieve better image 

clarity, reliability and speed are being 

constantly pursued by medical imaging 

companies. Technologies that offer such 

improvements therefore present 

excellent commercial potential. Thus 

the subject invention which can be 

applied in a broad spectrum of imaging 

technologies offers such good 

commercial potential. 

Inventors: Han Wen and Vinay Pai 

(NHLBI). 

Relevant Articles 

1. Fish DA, Grochmalicki J, Pike ER. 

Scanning singular-value-decomposition 

method for restoration of images with 

space-variant blur. J Opt Soc Am A, 

13(3), pp. 464–469, March 1996. 

2. Du X, Dunxu Y, Cuihua L, Jing L. 

‘‘A novel approach to SVD-based image 

filtering improvement,’’ International 

Conference on Computer Science and 

Software Engineering, vol 6, pp. 133– 

136, 2008. 

Patent Status: U.S. Provisional 

Application No. 61/266,442 filed 03 Dec 

2009 (HHS Reference No. E–292–2009/ 

0–US–01). 

Related Technologies: Image 

denoising techniques such as singular 

value decomposition (SVD). 

Licensing Status: Available for 

licensing. 

Licensing Contacts 

• Uri Reichman, PhD, MBA; 301– 

435–4616; UR7a@nih.gov. 

• John Stansberry, PhD; 301–435– 

5236; stansbej@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Heart, Lung, and Blood 

Institute is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

implement the technology described 

above on specific commercial platforms. 

Please contact Denise Crooks, PhD at 

301–435–0103 or via e-mail at 

crooksd@nhlbi.nih.gov for more 

information. 

Inverse Agonists of the TSH Receptor 

for the Treatment of Thyroid Cancer 

and Hyperthyroidism 

Description of Invention: This 

technology features small molecule 

inverse agonists of the thyroidstimulating hormone (TSH) receptor 

that may be readily synthesized, and are 

likely to prove effective for oral 

administration. These compounds may 

potentially be used to treat recurrent 

thyroid cancer and some cases of 

hyperthyroidism, and also represent 

unique tools for investigating the role of 

TSH receptor signaling in these 

diseases. 

According to the National Cancer 

Institute, over 37,000 new cases of 

thyroid cancer were diagnosed in the 

United States in 2008. Approximately 

10% to 30% of patients thought to be 

disease-free after initial treatment will 

develop recurrent cancer or metastases, 

and unless the recurrence is detected 

early, the prognosis is generally poor. 

As the TSH receptor is known to 

stimulate proliferation of thyroid cancer 

cells, it has been suggested that 

suppression of basal TSH receptor 

signaling may improve outcomes in the 

treatment of recurrent thyroid cancer. 

The compounds disclosed in this 

technology suppress basal signaling by 

the TSH receptor, and are thus excellent 

candidates for a suppression-based 

treatment approach. 

Applications 

• Lead compounds for the 

development of therapeutics for 

recurrent or metastatic thyroid cancer. 

• Lead compounds for the 

development of therapeutics for 

hyperthyroidism associated with 

constitutive TSH receptor signaling. 

• Tool for probing the role of basal 

TSH signaling in normal endocrine 

function and in disease states. 

Development Status: In vitro studies 

in primary human thyrocytes have been 

performed. 

Inventors: Marvin C. Gershengorn and 

Susanne Neumann (NIDDK); Wenwei 

Huang and Craig J. Thomas (NHGRI). 

Relevant Publications 

1. S Neumann, W Huang, E Eliseeva, 

S Titus, CJ Thomas, MC Gershengorn. A 

small molecule inverse agonist for the 

human thyroid-stimulating hormone 

receptor. Endocrinology. 2010 

Jul;151(7):3454–3459. [PubMed: 

20427476] 

2. S Moore, H Jaeschke, G Kleinau, S 

Neumann, S Costanzi, JK Jiang, J 

Childress, BM Raaka, A Colson, R 

Paschke, G Krause, CJ Thomas, MC 

Gershengorn. Evaluation of smallmolecule modulators of the luteinizing 

hormone/choriogonadotropin and 

thyroid stimulating hormone receptors: 

Structure-activity relationships and 

selective binding patterns. J Med Chem. 

2006 Jun 29;49(13):3888–3896. 

[PubMed: 16789744] 

3. S Neumann, G Kleinau, S Costanzi, 

S Moore, BM Raaka, CJ Thomas, G 

Krause, MC Gershengorn. A low 

molecular weight antagonist for the 

human thyrotropin receptor with 

therapeutic potential for 

hyperthyroidism. Endocrinology. 2008 

Dec;149(12):5945–5950. [PubMed: 

18669595] 

Patent Status: U.S. Provisional 

Application No. 61/322,138 filed 08 Apr 

2010 (HHS Reference No. E–067–2010/ 

0–US–01). 

Related Technologies 

• HHS Reference No. E–223–2006/0. 

• HHS Reference No. E–223–2006/1. 

• HHS Reference No. E–284–2008/0. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Tara Kirby, PhD; 

301–435–4426; tarak@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIDDK Office of Technology 

Transfer and Development is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop inverse 

agonists of the TAS receptor. Please 

contact Marguerite J. Miller at 301–496– 

9003 or millermarg@mail.nih.gov for 

more information. 

Small-Molecule TSH Receptor 

Modulators for Diagnosis and 

Treatment of Thyroid Disease and 

Cancer 

Description of Invention: NIH 

investigators have discovered a series of 

low molecular weight thyroidstimulating hormone (TSH) receptor 

modulators for use in evaluation and 

treatment of thyroid diseases, including 

thyroid cancer, hypothyroidism, and 

hyperthyroidism. Certain compounds 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices 63843 

encompassed by this technology are 

more potent and/or more specific TSH 

receptor activators than currentlyavailable compounds; also, as small 

molecules, these compounds are orally 

available and are expected to be less 

costly and more straightforward to 

produce than recombinant protein 

counterparts currently on the market. 

According to the National Cancer 

Institute, over 37,000 new cases of 

thyroid cancer were diagnosed in the 

United States in 2008, and over 1,500 

people died of this disease. These 

numbers reflect a progressive increase 

in the incidence of thyroid cancer over 

the last several years. Because most 

cases of thyroid cancer are diagnosed in 

patients between the ages of 20 and 54, 

these patients will undergo decades of 

follow-up monitoring after cancer 

treatment. For the last decade, 

recombinant TSH protein has been used 

in this follow-up to increase detection 

sensitivity for recurrent or metastatic 

thyroid cancer, and to eliminate side 

effects associated with withdrawal of 

hormone replacement therapy. A smallmolecule TSH receptor agonist 

encompassed by this technology would 

have utility similar to recombinant TSH, 

but would have several distinct 

advantages. For example, as a small 

molecule, rather than a recombinant 

protein, such a compound would be 

orally available, and would be less 

difficult and expensive to produce. 

These compounds are also more potent 

and/or specific for the TSH receptor 

than other known small-molecule TSH 

receptor agonists. In addition to use in 

thyroid cancer screening, these 

compounds may also be useful for 

adjunctive treatment (with radioactive 

iodide) of thyroid cancer, and certain 

forms of hypothyroidism. 

Hyperthyroidism, or an overactive 

thyroid gland, affects about 1% of 

people in the United States and is often 

caused by autoimmune over-stimulation 

of the thyroid gland (Graves’ disease), or 

by thyroid tumors. Drugs currently used 

for treatment of hyperthyroidism inhibit 

synthesis of thyroid hormones; the TSH 

receptor antagonist compounds 

encompassed by this technology have 

the advantage of directly inhibiting 

activity of the TSH receptor, rather than 

inhibiting thyroid hormone synthesis. 

Applications 

• Diagnostic tools for evaluation and 

treatment of thyroid cancer. 

• Therapeutics for thyroid cancer, 

hyperthyroidism, and hypothyroidism. 

Market: Approximately 1 in 13 

Americans suffers from a thyroid 

disorder, and 10 million have a thyroidrelated condition that requires ongoing 

immunodiagnostic monitoring. 

Development Status: Early stage. 

Inventors: Marvin C. Gershengorn et 

al. (NIDDK) 

Publications 

1. Moore S, Jaeschke H, Kleinau G, 

Neumann S, Costanzi S, Jiang JK, 

Childress J, Raaka BM, Colson A, 

Paschke R, Krause G, Thomas CJ, 

Gershengorn MC. Evaluation of smallmolecule modulators of the luteinizing 

hormone/choriogonadotropin and 

thyroid stimulating hormone receptors: 

structure-activity relationships and 

selective binding patterns. J Med Chem. 

2006 Jun 29;49(13):3888–3896. 

[PubMed: 16789744] 

2. Neumann S, Kleinau G, Costanzi S, 

Moore S, Raaka BM, Thomas CJ, Krause 

G, Gershengorn MC. A low molecular 

weight antagonist for the human 

thyrotropin receptor with therapeutic 

potential for hyperthyroidism. 

Endocrinology 2008 Dec;149(12):5945– 

5950. [PubMed: 18669595] 

3. Unpublished data are also available 

for review under a CDA. 

Patent Status 

HHS Reference Nos. E–223–2006/0 

and E–223–2006/1— 

• International Patent Application 

No. PCT/US2007/011951 filed 17 May 

2007, which published as WO 2007/ 

136776 on 29 Nov 2007 

• National Phase entered in Australia, 

Canada, Europe, Japan, and the United 

States 

HHS Reference No. E–284–2008/0— 

• International Patent Application 

No. PCT/US2008/011958 filed 20 Oct 

2008. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Tara L. Kirby, PhD; 

301–435–4426; tarak@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIDDK Clinical Endocrinology 

Branch is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize small molecule TSH 

receptor modulators. Please contact 

Marguerite J. Miller at 301–496–9003 or 

millermarg@mail.nih.gov for more 

information. 

Dated: October 12, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–26160 Filed 10–15–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; Review of Minority Biomedical 

Research Neuro Grant Applications. 

Date: November 12, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency-Bethesda, 7400 

Wisconsin Avenue, One Bethesda Metro 

Center, Bethesda, MD 20814. 

Contact Person: John J. Laffan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 

Natcher Building, Room 3AN18J, Bethesda, 

MD 20892, 301–594–2773, 

laffanjo@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: October 12, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–26185 Filed 10–15–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; 

Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute of 

mstockstill on DSKH9S0YB1PROD with NOTICES